Vaxcyte (PCVX) Stock Price, News & Analysis

Company Overview

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Key Stats

• Today's Range: $71.69 to $76.51
• 50-Day Range: $68.89 to $92.13
• 52-Week Range: $58.10 to $121.06
• Volume: 947,041 shs
• Average Volume: 1.19 million shs
• Market Capitalization: $9.40 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $147.50
• Consensus Rating: Buy

Vaxcyte Stock Analysis - MarketRank™

Vaxcyte scored higher than 47% of companies evaluated by MarketBeat, and ranked 611th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Vaxcyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vaxcyte has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Vaxcyte are expected to decrease in the coming year, from ($4.21) to ($4.49) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaxcyte is -15.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaxcyte is -15.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vaxcyte has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.21% of the float of Vaxcyte has been sold short.

Short Interest Ratio / Days to Cover

Vaxcyte has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Vaxcyte has recently decreased by 7.50%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaxcyte does not currently pay a dividend.

Dividend Growth

Vaxcyte does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.21% of the float of Vaxcyte has been sold short.

Short Interest Ratio / Days to Cover

Vaxcyte has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Vaxcyte has recently decreased by 7.50%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.47

News Sentiment

Vaxcyte has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Vaxcyte this week, compared to 6 articles on an average week.

Search Interest

Only 3 people have searched for PCVX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,550,258.00 in company stock.

Percentage Held by Insiders

Only 3.10% of the stock of Vaxcyte is held by insiders.

Percentage Held by Institutions

96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PCVX Stock Analysis - Frequently Asked Questions

How have PCVX shares performed this year?

Vaxcyte's stock was trading at $81.86 on January 1st, 2025. Since then, PCVX shares have decreased by 10.8% and is now trading at $73.02.
View the best growth stocks for 2025 here.

How were Vaxcyte's earnings last quarter?

Vaxcyte, Inc. (NASDAQ:PCVX) issued its quarterly earnings data on Tuesday, February, 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.14.

When did Vaxcyte IPO?

Vaxcyte (PCVX) raised $210 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 14,000,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO and Cantor and Needham & Company were co-managers.

Who are Vaxcyte's major shareholders?

Vaxcyte's top institutional investors include FMR LLC (10.50%), Vanguard Group Inc. (9.60%), Janus Henderson Group PLC (8.48%) and Capital Research Global Investors (4.98%). Insiders that own company stock include Jeff Fairman, Jim Wassil, Grant Pickering, Andrew Guggenhime, Mikhail Eydelman, Paul Sauer, Elvia Cowan, Teri Loxam, Halley E Gilbert and Heath Lukatch.
View institutional ownership trends.

How do I buy shares of Vaxcyte?

Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vaxcyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxcyte investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 2/25/2025
• Today: 3/13/2025
• Next Earnings (Estimated): 5/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PCVX
• CIK: 1649094
• Web: www.vaxcyte.com
• Phone: 650-837-0111
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $147.50
• High Stock Price Target: $163.00
• Low Stock Price Target: $129.00
• Potential Upside/Downside: +101.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-402,270,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -23.53%
• Return on Assets: -22.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.88
• Quick Ratio: 17.88

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.04 per share
• Price / Book: 5.62

Miscellaneous

• Outstanding Shares: 128,762,000
• Free Float: 120,773,000
• Market Cap: $9.43 billion
• Optionable: Optionable
• Beta: 1.02